

SmartPA Criteria Proposal

| | |
|-----------------------------------|--|
| Drug/Drug Class: | Glaucoma Agents PDL Edit |
| First Implementation Date: | January 5, 2012 |
| Proposed Date: | April 18, 2023 |
| Prepared For: | MO HealthNet |
| Prepared By: | MO HealthNet/Conduent |
| Criteria Status: | <input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria |

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: Glaucoma is the second most common cause of permanent blindness in the United States. Increased intraocular pressure (IOP) is common in glaucoma and is believed to contribute to the damage to the optic nerve which can lead to loss of visual sensitivity and field. It was once thought that high IOP was the main cause of this optic nerve damage. Although IOP is clearly a risk factor, it is now known that other factors must also be involved because even people with "normal" levels of pressure can experience vision loss from glaucoma. Several types of medications are used to treat glaucoma, including beta-blockers, sympathomimetics, topical carbonic anhydrase inhibitors, direct/indirect cholinergic agonists, and prostaglandin analogs. Monotherapy or combination therapy may be used to treat and delay the need for surgery and to prevent functional vision loss. All medications used for the management of glaucoma attempt to limit further damage to the optic nerve.

Total program savings for the PDL classes will be regularly reviewed.

| Program-Specific Information: | Preferred Agents | Non-Preferred Agents |
|-------------------------------|---|--|
| | <ul style="list-style-type: none"> Latanoprost | <ul style="list-style-type: none"> Bimatoprost Durysta® Lumigan® Rhopressa® Rocklatan® Simbrinza® Tafluprost Travatan-Z® Travoprost Vyzulta® Xalatan® Xelpros™ Zioptan® |

Type of Criteria: ☐ Increased risk of ADE ☒ Preferred Drug List
☐ Appropriate Indications ☐ Clinical Edit

Data Sources: ☐ Only Administrative Databases

☒ Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Glaucoma Agents
- Age range: All appropriate MO HealthNet participants

Approval Criteria

- For non-preferred agents:
 - For Rhopressa, Rocklatan or Simbrinza therapy:
 - Documented compliance on current therapy regimen **OR**
 - Adequate therapeutic trial of 1 prostaglandin agent AND 1 beta-adrenergic blocking agent **OR**
 - Failure to achieve desired therapeutic outcomes with trial on 1 or more preferred agents
 - Documented trial period for preferred agents **OR**
 - Documented ADE/ADR to preferred agents **AND**
 - For Durysta: Clinical Consultant Review required if participant history demonstrates prior claim for bimatoprost intracameral implant

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results: ☐
MedWatch Form: ☐

Progress Notes: ☐
Other: ☐

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

- Evidence-Based Medicine and Fiscal Analysis: "Therapeutic Class Review: Ophthalmic: Glaucoma, Prostaglandin Agonists", Gainwell Technologies; Last updated February 15, 2023.
- Evidence-Based Medicine and Fiscal Analysis: "Therapeutic Class Review: OPHTHALMIC: Glaucoma, Rho Kinase (ROCK Inhibitors)", Gainwell Technologies; Last updated January 16, 2023.
- Evidence-Based Medicine Analysis: "Glaucoma Agents", UMKC-DIC; Last updated October 2022.
- USPDI, Micromedex; 2023.
- Facts and Comparisons eAnswers (online); 2023 Clinical Drug Information, LLC.

SmartPA PDL Proposal Form

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.
Other company trademarks are also acknowledged.